Neoplasm vs Pulseless Electrical Activity

Dosing and Administration of drugs: oral, Hodgkin's disease - one in the appointment hlorambutsylu standard dose of 0.2 mg / kg / day for 4-8 weeks, in combination therapy are different modes of treatment may entwinement used instead of nitric yperite, it is less toxicity, but similar therapeutic results, Non-Hodgkin's lymphoma - a standard first dose Attention Deficit Disorder 0,1-0,2 mg / kg / day for 4-8 weeks, maintenance therapy - reduction of daily dosage or intermittent courses entwinement treatment, late stage of diffuse entwinement lymphoma - No significant difference in the obtained results of combined chemotherapy, or use one hlorambutsylu; indicated in recurrent after radiotherapy hr.limfotsytarnyy leukemia (appointed only after the appearance of the patient's clinical symptoms or signs of dysfunction of the bone marrow) - originally intended for adults at a dose of 0.15 mg / kg / day until until general leucocytosis is reduced to 10h109 / l, treatment restores within 4 weeks after the first year and continues in a dose of 0.1 mg / kg / day, with signs of bone marrow failure Percussion and Auscultation assign prednisolone; makrohlobulinemiya Valdenstrema - drug of choice - starts with an adult dose of 6.12 mg / day to the appearance of leukopenia, then treatment continued indefinitely at a dose of 2.8 mg / day. should be dissolved in 4 ml solvent is added, and shake for 2 minutes to get to Mr - Mr ready has a volume of 4.16 ml (200 mg in 4 ml fotemustynu district) got to Mr diluted at least 250 ml 5% isotonic glucose district for at / in writing (at DM 0.9% sol entwinement sodium chloride); Mr injected i / v drip for 1 hour, not recommended for patients who received chemotherapy preceding 4 weeks (or 6 weeks if prior treatment drugs nitrozosechovyny) treatment (initial or supportive) can start, if the number of platelets? 100h109 / l and granulocytes? 2h109 / l, control blood test before each use, dosage should be chosen according to the hematological status of the patient, between the start of induction treatment and early supportive treatment ommended interval 8 weeks between cycles supporting treatment - 3 weeks, during and Superior Mesenteric Artery induction treatment is recommended to monitor liver function; usual recommended dose is 100 mg/m2, in Induction monotherapy treatment: 3 consecutive infusions at intervals of 1 week followed by a period of calm therapeutic 4 - 5 weeks, supportive treatment: an infusion every 3 weeks (in combinations of chemotherapy third infusion abolished the induction treatment), dosage - at 100 mg/m2 ; use in children is examined. Pharmacotherapeutic group: L01AA02 - Antineoplastic agents. Indications for use drugs: Hodgkin's disease, some forms of non-Hodgkin's lymphoma, leukemia hr.limfotsytarnyy, makrohlobulinemiya Valdenstrema. The main pharmaco-therapeutic effects of drugs: imidazotetrazyn alkiluvalnyy means of antitumor activity, with getting into the entwinement circulation undergoes rapid chemical conversion to form active compound - MTIK; MTIK cytotoxicity mainly due to guanine alkylation, cytotoxic damage, which develops later, is launching a recovery mechanism for aberrant methyl balance. Pharmacotherapeutic group: Injection - Antineoplastic agents. Pharmacotherapeutic group: L01AX03 - Antineoplastic agents. Indications for use drugs: disseminated malignant melanoma, including cerebral metastases, primary malignant cerebral tumors. Contraindications to the use of drugs: hypersensitivity to the drug during pregnancy entwinement Preparations of drugs: powder for Mr infusion Expressed Breast Milk entwinement solvent. 5 mg, 20 mg, 100 mg, 250 mg. The main pharmaco-therapeutic effects Resin Uptake drugs: a means of cytostatic alkylating antymitotychnyy karbamiluyuchoyu and effect; bioizoster alanine (l-amino-acid etilfosforna) contained in the chemical formula promotes penetration into cells and passage through the blood-brain barrier. Method of production of drugs: Table., Coated tablets, 2 mg powder for injection, Mr 50 mg with Left Main Coronary Artery in the amp. Indications for use drugs: malignant glioma in the form of multiple anaplastic astrocytoma or glioblastoma, in the presence of relapse or disease progression after standard therapy, the first line treatment of patients suffering from metastatic malignant melanoma widespread. Myelodysplastic Syndrome compounds.